Santander's board has approved an interim cash dividend of 0.115 euros per share against its 2025 results, up 15% from a year earlier, the Spanish bank said on Tuesday. ...

British Prime Minister Keir Starmer triggered fury Today as he revealed plans for UK digital ID, but are major banks planning to take the British pound (GBP) digital too? Britain’s biggest banks have launched live tests of “tokenized” sterling, digital versions of bank deposits designed for faster and more controlled payments. (Source – GBP USD, TradingView) Six lenders, Barclays, HSBC, Lloyds Banking Group, NatWest, Nationwide, and Santander, are taking part in the pilot, which is being coordinated b ...

Banco Santander, S.A. (NYSE:SAN) is one of the stocks Jim Cramer offered insights on. A club member asked if it makes sense to continue buying SAN shares, and he stated: “Okay, Banco Santander is the largest bank in Europe. This is run by Ana Botín. It’s a sensational bank… But I will say this, at $10, you should wait till it goes back to 9. I’m not kidding. I’ve watched the stock climb and climb and climb. It had a little bit of a spike. I don’t like that. Under 9 would be a terrific level. Still got a g ...

Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation The fund will remain focused on Sanofi's key areas of immunology, rare diseases, neurology, and vaccines, backing earlier-stage innovation and emerging opportunities that support the company’s long-term strategySanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies Paris, September 24, 2025. Sanofi Ventures ...

Availability of the Q3 2025 Aide mémoire Paris, France – September 24, 2025. Sanofi announced today that its Q3 2025 Aide mémoire is available on the "Investors" page of the company's website: Third quarter 2025 (sanofi.com) As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items, as well as the foreign currency impact and share count. Sanofi's second quarter 2025 results wil ...

PresentationMy pleasure to kick off the next session. It's Sachin Jain here from European team at Bank of America. My pleasure to be hosting Paul Hudson, CEO of Sanofi, we have 40 minutes. I think, Paul, perhaps some interim commentary and then we'll get into Q&A. So with that, over to you.Paul HudsonCEO & Director So it's been an interesting year for me and for us. And while we've advanced the pipeline quite significantly. The only thing that's really irritating me was the itepekimab readout with 1 positiv ...

核心观点 - 美国FDA授予赛诺菲基因疗法SAR446268快速通道资格 用于治疗非先天性1型强直性肌营养不良症(DM1) [1] - 该疗法采用RNA干扰技术靶向沉默DMPK基因表达 是目前唯一进入临床研究阶段的DM1候选疗法 [2][7] - 全球DM1患者发病率约为1/2300 目前尚无任何获批治疗方案 [4][7] 产品特性 - 采用腺相关病毒载体(AAV)递送RNA干扰(RNAi)技术 通过单次给药实现DMPK基因沉默 [2] - 作用机制为减少DMPK转录本 消除肌肉组织中有毒RNA foci 恢复正常剪接功能并改善肌肉功能 [2] - 针对疾病核心症状包括进行性肌无力、肌强直以及心脏/肺部/内分泌系统等多系统功能障碍 [2][4] 临床进展 - 目前处于首次人体I/II期临床研究阶段(NCT06844214) 重点评估安全性、耐受性和有效性 [3] - 首例患者计划于2025年末入组 [3] - 已获得美国(2024年7月)和欧盟(2024年10月)孤儿药资格认定 [3] 疾病背景 - 1型强直性肌营养不良症(Steinert病)为遗传性进行性罕见疾病 由DMPK基因突变引起 [4] - 临床表现包括从轻度成人病例到严重先天性形式的不同程度症状 严重影响患者日常生活能力和独立功能 [4] - 疾病可发生于任何年龄段 对维持生命重要功能产生深远影响 [4] 公司战略 - 赛诺菲定位为研发驱动型人工智能生物制药企业 专注于免疫系统相关药物和疫苗开发 [5] - 公司致力于通过解决最紧迫的医疗健康挑战来推动进步并产生积极影响 [5] - 在泛欧交易所(EURONEXT: SAN)和纳斯达克(NASDAQ: SNY)双重上市 [6]

监管进展 - 欧洲药品管理局人用药品委员会采纳积极意见 推荐批准Dupixent用于治疗慢性自发性荨麻疹 覆盖12岁及以上中重度患者群体[1] - 最终批准决定预计在未来几个月内做出[1] - 若获批 Dupixent将成为欧盟十余年来首个针对慢性自发性荨麻疹的靶向药物[10] 临床试验数据 - 支持意见的数据来自LIBERTY-CUPID三期项目中的两项研究(NCT04180488 A研究和C研究)[2] - 研究显示Dupixent在24周时相比安慰剂显著减少瘙痒和荨麻疹症状[2][10] - 项目中的B研究在不同患者群体中提供了额外安全性数据[2] - 安全性结果与已知安全性特征基本一致 成人及青少年患者中发生率≥5%的不良事件包括注射部位反应、COVID-19感染、高血压、慢性自发性荨麻疹和意外过量[3] 产品特性与适应症 - Dupixent是全人源单克隆抗体 通过抑制白细胞介素4和白细胞介素13信号通路发挥作用 非免疫抑制剂[6] - 目前已在包括日本和美国在内的多个国家获批用于特定成人和青少年慢性自发性荨麻疹患者[4] - 全球超过60个国家批准用于一种或多种适应症 包括特应性皮炎、哮喘、慢性鼻窦炎伴鼻息肉、嗜酸性食管炎、结节性痒疹、慢性自发性荨麻疹、慢性阻塞性肺病和大疱性类天疱疮[7] - 全球正在接受治疗的患者超过100万人[7] 疾病背景 - 慢性自发性荨麻疹是慢性炎症性皮肤疾病 部分由2型炎症驱动 导致突发性虚弱性荨麻疹和反复发作的瘙痒[5] - 标准治疗为靶向H1受体的抗组胺药 但许多患者症状仍无法控制[5] 研发合作与管线 - Dupilumab由赛诺菲和再生元根据全球合作协议共同开发[8] - 迄今已在60多项临床研究中涉及超过10,000名患有2型炎症相关慢性疾病的患者[8] - 除已批准适应症外 正在进行三期研究的疾病包括未知原因慢性瘙痒和慢性单纯性苔藓[9] 公司背景 - 再生元(NASDAQ: REGN)是领先的生物技术公司 专注于为严重疾病患者开发变革性药物[11] - 利用VelociSuite等专有技术生产优化全人源抗体和新型双特异性抗体[12] - 赛诺菲(EURONEXT: SAN, NASDAQ: SNY)是研发驱动型生物制药公司 专注于免疫系统相关药物和疫苗开发[14][15]

Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo If approved, Dupixent would be the first targeted medicine in over a decade indicated for CSU in the European Union (EU) TARRYTOWN, N.Y. and PARIS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted ...

交易概述 - 美国银行同意从桑坦德银行收购价值1亿欧元（1.18亿美元）的西班牙房地产贷款组合[1] - 这是美国银行今年与桑坦德银行达成的第二笔类似交易[1] - 交易由高力国际集团提供咨询支持[1] 美国银行战略动机 - 收购旨在欧洲利率变动导致房地产资产重新定价之际 获得西班牙房地产贷款市场的立足点[3] - 通过专业房地产贷款扩张实现资产基础多元化 并获取欧洲商业房地产贷款的更高收益[3] - 今年早些时候已从桑坦德银行收购酒店相关贷款组合[3] 桑坦德银行战略目标 - 交易是桑坦德银行2025年剥离400-450亿欧元风险加权资产计划的一部分[1] - 通过出售贷款组合和风险转移加强资本比率 为核心贷款业务释放资源[4] - 除美国银行外 近期还向高盛和摩根士丹利出售不良贷款组合[4] 同业交易动态 - 高盛从桑坦德银行收购约4.6亿欧元（5.34亿美元）西班牙抵押贷款[5] - 摩根士丹利以9亿欧元与桑坦德银行达成交易 并从其他西班牙银行收购不良抵押贷款组合[5] 市场表现 - 美国银行股价过去六个月上涨22.7% 低于行业28.9%的涨幅[6]